How the clinical research community responded to the COVID-19 pandemic : An analysis of the COVID-19 clinical studies in ClinicalTrials.gov
OBJECTIVE: The novel coronavirus disease (COVID-19), broke out in December 2019, and is now a global pandemic. In the past few months, a large number of clinical studies have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies for COVID-19. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the gaps such as the lack of population representativeness and issues that may cause recruitment difficulty.
MATERIALS AND METHODS: We analyzed 3,765 COVID-19 studies registered in the largest public registry - ClinicalTrials.gov, leveraging natural language processing and using descriptive, association, and clustering analyses. We first characterized COVID-19 studies by study features such as phase and tested intervention. We then took a deep dive and analyzed their eligibility criteria to understand whether these studies: (1) considered the reported underlying health conditions that may lead to severe illnesses, and (2) excluded older adults, either explicitly or implicitly, which may reduce the generalizability of these studies to the older adults population.
RESULTS: Most trials did not have an upper age limit and did not exclude patients with common chronic conditions such as hypertension and diabetes that are more prevalent in older adults. However, known risk factors that may lead to severe illnesses have not been adequately considered.
CONCLUSIONS: A careful examination of existing COVID-19 studies can inform future COVID-19 trial design towards balanced internal validity and generalizability.
| Errataetall: |
UpdateIn: JAMIA Open. 2021 Apr 20;4(2):ooab032. - PMID 34056559 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2020) vom: 15. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Zhe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 10.11.2023 published: Electronic UpdateIn: JAMIA Open. 2021 Apr 20;4(2):ooab032. - PMID 34056559 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.09.16.20195552 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315663804 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315663804 | ||
| 003 | DE-627 | ||
| 005 | 20231225155416.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.16.20195552 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315663804 | ||
| 035 | |a (NLM)32995807 | ||
| 035 | |a (PII)2020.09.16.20195552 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Zhe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How the clinical research community responded to the COVID-19 pandemic |b An analysis of the COVID-19 clinical studies in ClinicalTrials.gov |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: JAMIA Open. 2021 Apr 20;4(2):ooab032. - PMID 34056559 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVE: The novel coronavirus disease (COVID-19), broke out in December 2019, and is now a global pandemic. In the past few months, a large number of clinical studies have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies for COVID-19. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the gaps such as the lack of population representativeness and issues that may cause recruitment difficulty | ||
| 520 | |a MATERIALS AND METHODS: We analyzed 3,765 COVID-19 studies registered in the largest public registry - ClinicalTrials.gov, leveraging natural language processing and using descriptive, association, and clustering analyses. We first characterized COVID-19 studies by study features such as phase and tested intervention. We then took a deep dive and analyzed their eligibility criteria to understand whether these studies: (1) considered the reported underlying health conditions that may lead to severe illnesses, and (2) excluded older adults, either explicitly or implicitly, which may reduce the generalizability of these studies to the older adults population | ||
| 520 | |a RESULTS: Most trials did not have an upper age limit and did not exclude patients with common chronic conditions such as hypertension and diabetes that are more prevalent in older adults. However, known risk factors that may lead to severe illnesses have not been adequately considered | ||
| 520 | |a CONCLUSIONS: A careful examination of existing COVID-19 studies can inform future COVID-19 trial design towards balanced internal validity and generalizability | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a eligibility criteria | |
| 650 | 4 | |a natural language processing | |
| 700 | 1 | |a Erdengasileng, Arslan |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Aiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Charness, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Jiang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2020) vom: 15. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.16.20195552 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 15 |c 12 | ||